5-Amino-1MQ
5-Amino-1MQ is supplied as an NNMT-enzyme inhibitor for cellular energy-metabolism and NAD+-pathway research. Supplied strictly for laboratory and educational research. Not for human or veterinary use.
Vial amount
Purchase option
Checkout includes a research-use attestation. Materials are supplied only for laboratory and educational research.
5-Amino-1MQ in research
5-Amino-1MQ is supplied as an NNMT-enzyme inhibitor for cellular energy-metabolism and NAD+-pathway research.
General RUO catalog item for documented laboratory workflows.
Bench context
Supplied as a research-grade reference material for documented laboratory and educational research workflows.
Available amounts
Select from the stocked vial amounts for 5-Amino-1MQ before adding the material to cart.
Claims discipline
No protocol instructions, no dosing, no medical advice, and no therapeutic or human-use promises.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a drug or supplement.
As listed by the supplier in BioRegen's ordering system, shown here exactly as written for transparency. This is the vendor's own description, not independently verified, edited, or endorsed by BioRegen, and is not a BioRegen claim of any effect.
10mg
10mg
50mg
50mg
The full research picture, clearly labeled
BioRegen reports the entire research landscape for this compound across four clearly separated tiers, strongest evidence first. Lower tiers, including community and anecdotal reports, are labeled as such and are not BioRegen claims.
No human clinical trials of 5-Amino-1MQ have been reported in the peer-reviewed literature to date. There is therefore no controlled human efficacy or safety data on which to draw, and any account of human effects would be speculative. Investigators describe the molecule as research-stage, with the existing evidence base confined to laboratory and animal models rather than registered trials.
5-Amino-1MQ is described in published research as a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme implicated in NAD+ salvage and cellular metabolism. Neelakantan and colleagues reported that selective, membrane-permeable small-molecule NNMT inhibitors of this class reversed high-fat-diet-induced obesity in mice (Neelakantan et al., Biochemical Pharmacology, 2018, doi:10.1016/j.bcp.2017.11.007). This builds on earlier work by Kraus and colleagues, who reported that NNMT knockdown protected mice against diet-induced obesity (Kraus et al., Nature, 2014, doi:10.1038/nature13198). These findings are from cell and rodent models and have not been extended to humans.
Within fat-loss and NAD-focused biohacker communities and longevity forums, 5-Amino-1MQ is discussed as a metabolism and body-composition compound, often in connection with NAD+ support. Such discussion reflects individual self-experimentation and online commentary rather than measured outcomes, and these venues are not a substitute for the controlled preclinical record. Reports of this kind are unverified anecdotal commentary, not controlled data, and not a BioRegen claim.
5-Amino-1MQ is not approved by the FDA for any use and is not an approved drug, dietary supplement, or food ingredient. It carries no recognized therapeutic indication and has not undergone regulatory review for human administration. BioRegen supplies it strictly for laboratory and educational research, not for human use.
Tiers are evidence categories, not endorsements. Clinical and preclinical entries summarize third-party published research. Community and anecdotal entries are unverified reports discussed by others, not findings and not BioRegen claims. Nothing here is medical advice, and no compound is approved for human or veterinary use except where explicitly stated under Regulatory status.
What the published research says about 5-Amino-1MQ
This section reports on published research referenced in BioRegen's own research library. It is not a claim by BioRegen that the compound provides any benefit, and nothing here is medical advice.
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol . 2018. doi:10.1016/j.bcp.2017.11.007
- Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature . 2014. doi:10.1038/nature13198